PDCD1 and hepatocellular carcinoma: This retrospective study showed that the combined HAIC, TKI, and PD-1 inhibitor therapy was efficient in patients with u-HCC and that patients with CPA had better treatment responses, fewer AEs, and longer PFS than patients with CPB.